Larvol Delta - Catapult-Therapeutics-receives-FDA-Clearance-of-Investigational-New-Drug-IND-Application-for-CAP100-an-innovative-firstinclass-humanized-antiCCR7-antibody

CAP-100 - Catapult Therap

https://www.prnewswire.com/news-releases/catapult-therapeutics-receives-fda-clearance-of-investigational-new-drug-ind-application-for-cap-100-an-innovative-first-in-class-humanized-anti-ccr7-antibody-301223908.html

Feb 8, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next